About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

NVAMD Satellite Study | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT02251366

NVAMD Satellite Study

Intravitreal delivery of anti-vascular endothelial growth factor (VEGF) drugs has revolutionized the management of neovascular age-related macular degeneration (NVAMD). However, the requirement for ne...

Lead sponsor: Johns Hopkins University•5 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Johns Hopkins University

Age

18 - 100 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Established diagnosis of NVAMD in one or both eyes
•Received 2 or more intravitreal injections of anti-VEGF therapy from the retinal physician during the prior 6 months
•Need for more therapy on a near monthly basis is anticipated
•Usual corrected visual acuity (UCVA) of at least one eye must be 20/200 or better
•Must be physically able to cooperate with OCT and other diagnostic imaging procedures
•Must be able to give informed consent and be able to complete telephone surveys

Exclusion Criteria

•Systemic disease that can affect the peripheral retina (e.g., diabetes mellitus, sickle cell)
•History of symptomatic posterior vitreous detachment, retinal tear, or retinal detachment
•History of retinal surgery will not be enrolled.

Related studies

Not Yet RecruitingPhase 4

A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)

NCT07365371 · Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)

COMPLETEDPhase 3

A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration

NCT04239027 · Neovascular Age Related Macular Degeneration

Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.

NCT01942213 · Neovascular Age Related Macular Degeneration

TERMINATEDPhase 4

TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection

NCT01983579 · Neovascular Age Related Macular Degeneration (AMD), Open Angle Glaucoma

COMPLETEDPhase 2

Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)

NCT01678963 · Neovascular Age Related Macular Degeneration

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 31, 2018Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment66

Start dateOct 2014

Last updatedAug 31, 2018

Condition

Neovascular Age Related Macular Degeneration

Locations shown

Wilmer Eye Institute

Bel Air, Maryland

Wilmer Eye Institute

Bethesda, Maryland

Wilmer Eye Institute

Columbia, Maryland

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 31, 2018Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions